“反内卷”催化，医疗器械本轮反弹超10%！医疗器械指数ETF（159898）6日累获近2400万元资金流入

Group 1 - The core viewpoint is that the medical device industry is entering a new phase of "quality-price balance" due to the optimization of centralized procurement rules, which will positively influence the healthy development of the pharmaceutical industry [1] - The 11th batch of centralized procurement has been initiated, with adjustments in the selection rules to no longer solely rely on the lowest bid as a reference, requiring the lowest bidder to justify their pricing [1] - The medical device index has rebounded over 10% since its low in June, indicating a positive market response, with the medical device index ETF (159898) experiencing a continuous inflow of 23.61 million yuan over six days [1] Group 2 - CITIC Securities believes that the "anti-involution" and "optimization of procurement not solely based on low prices" will lead to a recovery in sector valuations and performance certainty, with increasing opportunities in the medical device industry in the second half of the year [2] - The expectation is that several companies will experience high growth in Q3, driven by product innovation, internationalization, and mergers and acquisitions, which will open up long-term potential [2]